Objective: To investigate the mechanism of H. pylori NapA protein inducing the secretion of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) in macrophages. Methods: Macrophages were stimulated by NapA, then chemokines MCP-1 and IL-8 in supernatant were detected through ELISA. Macrophages were pre-incubated with C29, ST2825, SB203580, SP600125 and PDTC for 1 h to inhibit the activity of TLR2, MyD88, p38, c-Jun and NF-κB, respectively. Then NapA protein was added and incubated for 4 h. The supernatant was collected and the expression levels of MCP-1 and IL-8 were examined. Results: The expression levels of MCP-1 and IL-8 in macrophages stimulated by H. pylori NapA protein were significantly higher than those in untreated group. When the activity of TLR2 was inhibited by C29, the expression of MCP-1 and IL-8 induced by NapA protein decreased. Inhibition of MyD88 NF-κB and p38 decreased the ability of macrophages to secrete MCP-1 and IL-8 induced by NapA protein. However, inhibition of c-Jun did not affect the secretion of MCP-1 and IL-8 by macrophages induced by NapA protein. Conclusion: H. pylori NapA protein induces macrophages to secrete chemokines MCP-1 and IL-8 via TLR2/MyD88/NF-κB pathway.
LI Jie
,
YAN Jie
,
YANG Hongxia
. The mechanism of NapA protein inducing macrophages to secrete chemokine monocyte chemoattractant protein 1 and interleukin 8[J]. Journal of Baotou Medical College, 2024
, 40(8)
: 15
-20
.
DOI: 10.16833/j.cnki.jbmc.2024.08.004
[1] Bai XF, Zhu MJ, He YJ, et al.The impacts of probiotics in eradication therapy of Helicobacter pylori[J].Arch Microbiol, 2022, 204(12): 692.
[2] Díaz P, Valenzuela Valderrama M, Bravo J, et al.Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression[J].Front Microbiol, 2018, 9: 5.
[3] Hu Y, Zhu Y, Lun H.Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance[J].Front Cell Infect Microbiol, 2017, 7: 168.
[4] Hultenk G, Lamberthl B, Kalfusi N, et al.National and regional USantibiotic resistance to Helicobacter pylori:lessons from a clinical trial[J].Gastroenterology, 2021, 161(1): 342-344.e1.
[5] Fuh W, Laiy C.The role of Helicobacter pylori neutrophil-activating protein in the pathogenesis of H.pylori and beyond: from a virulence factor to therapeutic targets and therapeutic agents[J].Int J Mol Sci, 2022, 24(1): 91.
[6] Tsaic C, Kuot Y, Hongz W, et al.Helicobacter pylori neutrophil-activating protein induces release of histamine and interleukin-6 through G protein-mediated MAPKs and PI3K/Akt pathways in HMC-1 cells[J].Virulence, 2015, 6(8): 755-765.
[7] Zhao YC, Cai YY, Chen ZH, et al.SpoT-mediated NapA upregulation promotes oxidative stress-induced Helicobacter pylori biofilm formation and confers multidrug resistance[J].Antimicrob Agents Chemother, 2023, 65(5): e00152-e00121.
[8] Soleimani N, Mohabati Mobarez A, Tavakoli-Yaraki M, et al.Evaluation of nitric oxide production and proliferation activity of recombinant Bacterioferritin of Helicobacter pylori on macrophages[J].Microb Pathog, 2016, 100: 149-153.
[9] Fuh W.Helicobacter pylori neutrophil-activating protein: from molecular pathogenesis to clinical applications[J].World J Gastroenterol, 2014, 20(18): 5294-5301.
[10] Ramachandran M, Jin C, Yu D, et al.Correction: vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration[J].J Immunol, 2015, 194(11): 5568.
[11] Codolo G, Coletta S, D'Elios MM, et al.HP-NAP of Helicobacter pylori: The power of the Immunomodulation[J].Front Immunol, 2022, 13: 944139.
[12] Kayali S, Manfredi M, Gaiani F, et al.Helicobacter pylori, transmission routes and recurrence of infection: state of the art[J].Acta Biomed, 2018, 89(8-S): 72-76.
[13] Mejías-Luque R, Gerhard M.Immune evasion strategies and persistence of Helicobacter pylori[J].Curr Top Microbiol Immunol, 2017, 400: 53-71.
[14] Blaser N, Backert S, Pachathundikandis K.Immune cell signaling by Helicobacter pylori: impact on gastric pathology[J].Adv Exp Med Biol, 2019, 1149: 77-106.
[15] 刘凯雯, 刘志杰, 华甜.趋化因子受体的结构与信号转导机制[J].自然杂志, 2021, 43(1): 18-24.
[16] 黄秋月, 叶晖, 于靖, 等.幽门螺杆菌黏附素及其致病作用的研究进展[J].胃肠病学和肝病学杂志, 2019, 28(5): 563-567.
[17] Matsushima K, Yang D, Oppenheim JJ.Interleukin-8: An evolving chemokine[J].Cytokine, 2022, 153: 155828.
[18] Asami J, Shimizu T.Structural and functional understanding of the toll-like receptors[J].Protein Sci, 2021, 30(4): 761-772.
[19] Saikhk U.MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity[J].Immunol Res, 2021, 69(2): 117-128.
[20] Nemati M, Larussa T, Khorramdelazad H, et al.Toll-like receptor 2:an important immunomodulatory molecule during Helicobacter pylori infection[J].Life Sci, 2017, 178: 17-29.
